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The dysregulation of PD-1 ligands (PD-L1 and PD-L2) and CTLA-4 ligands (CD80 and CD86) represents a tumor strategy to
escape the immune surveillance. Here, the expression of PD-L1, PD-L2, CD80, and CD86 was evaluated at the mRNA level in 94
patients aﬀected by papillary thyroid carcinoma (PTC) and 11 patients aﬀected by anaplastic thyroid carcinoma (ATC).
Variations in the mRNAs in PTC patients were then correlated with clinicopathological features. The expression of all genes was
deregulated in PTC and ATC tissues compared to normal tissues. In particular, the downregulation of CD80 was observed
above all in ATC. In addition, the increased expression of CD80 associated with longer disease-free survival in PTC. Higher
expression of PD-L1 associated with the classical histological variant and with the presence of BRAFV600E mutation in PTC. The
increased PD-L2 expression correlated with BRAFV600E mutation and lymph node metastasis, while its lower expression
correlated with the follicular PTC variant. The latter was also associated with the CD80 downregulation, which was also related
to the absence of lymph node metastasis. In conclusion, we documented the overall dysregulation of PD-1 and CTLA-4 ligands
in PTC and ATC tissues and a possible prognostic value for CD80 gene expression in PTC.
1. Introduction
Based on experimental mouse models and clinical studies,
tumor inﬁltration by cells of the innate and adaptive arms
of the immune system is thought to reﬂect a physiological
attempt to eradicate incipient tumor, late-stage cancers, and
micrometastases [1–6]. According to the Cancer Immunoe-
diting Hypothesis, the tumor-immune system interaction is
divided into three stages: (i) elimination, in which the
immune system destroys cancer cells as they arise; (ii) equi-
librium, during which the selective pressure of the immune
system is thought to promote tumor cell variants capable of
evading the immune response; and (iii) escape, where cancer
cells are no longer subjected to the immune regulation and
tumors develop [7, 8]. The ability of highly immunogenic
cancer cells to avoid the immune destruction by disabling
components of the immune system is considered a hallmark
of cancer [9]. Malignant cells may inactivate cytotoxic T lym-
phocytes (CTL) and natural killer (NK) cells by secreting
immunosuppressive factors, such as TGF-β, indoleamine
2,3-dioxygenase, IL-10, and VEGF or through the recruit-
ment of immunosuppressive cells, myeloid-derived suppres-
sor cells (MDSCs), and regulatory T cells (Treg) [10–14].
Malignant cells may also express ligands for the immune
checkpoint CTLA-4 (cytotoxic T lymphocyte antigen 4) and
PD-1 (programmed cell death 1), present on the surface of
activated T lymphocytes, inhibiting their functions [14–19].
Eﬀective activation of T cells requires the engagement of
two separate T cell receptors. The antigen-speciﬁc T cell
receptor (TCR) binds foreign antigenic peptide-MHC
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complexes, and the CD28 receptor binds to the costimulatory
molecules CD80/CD86 (also known as B7.1/B7.2) expressed
on the surface of antigen-presenting cells (APC). The simul-
taneous triggering of these T cell surface receptors with their
speciﬁc ligands results in T cell activation. In contrast,
CTLA-4 (CD152) is a distinct T cell receptor that, upon bind-
ing to B7 molecules, elicits an inhibitory intracellular signal
[20]. Some studies indicated that B7-CTLA-4 interactions
may shield target tumor cells against cytotoxic T lympho-
cyte- (CTL-) mediated destruction [21].
Diﬀerently from B7, the ligands of PD-1, namely, PD-L1
and PD-L2, mediate only suppressive eﬀects on lymphocyte
functions by inhibiting the TCR signal. As a consequence,
the overexpression of PD-L1/PD-L2 at the surface of malig-
nant cells promotes immune evasion and tumor growth
[22]. Over the last few years, antibodies directed against
CTLA-4, PD-1, and PD-L1 have shown promising antitumor
activities in diﬀerent cancer types, and the Food and Drug
Administration (FDA) approved their use in patients aﬀected
by metastatic melanoma and lung cancer [23, 24].
Epithelial thyroid cancer accounts for roughly 1% of all
new malignant diseases and 0.4% of deaths related to cancer
(http://seer.cancer.gov/statfacts/html/thyro.html). Thyroid
tumors comprise the diﬀerentiated carcinomas (DTC), that
is, the papillary (PTC) and follicular (FTC) carcinomas, and
the poorly diﬀerentiated (PDTC) and the anaplastic (ATC)
thyroid carcinomas [25]. Diﬀerently from DTC, usually
showing a good prognosis, ATC is unresponsive to all cur-
rently available anticancer treatments and leads to death
within a few months from diagnosis [26, 27]. The actual stag-
ing system for DTC patients (i.e., TNM) incorporates in the
same risk group patients showing diﬀerent disease-speciﬁc
progression and survival time and fails to predict the risk of
cancer recurrences [26, 27]. Thus, the identiﬁcation of new
prognostic molecular markers able to testify thyroid tumor
aggressiveness is needed, as well as new therapeutic
approaches for the most advanced thyroid cancers [28–31].
A number of studies demonstrated the presence in thy-
roid cancer tissues of cells belonging to both the innate and
adaptive immune systems, including mast cells, NK cells,
macrophages, dendritic cells, and B and T cells. Despite that,
several experimental ﬁndings indicate that the immune
response in thyroid cancer is compromised [6, 32–38]. This
appears to be related to mechanisms of immune escape put
forward by cancer cells, which include the induction of T
lymphocyte dysfunction, recruitment of Treg, formation of
tolerogenic antigen-presenting cells (APC), and tumor cell
expression of immune checkpoint molecules [19, 33].
The analysis of PD-1 ligand expression and their
prognostic value is relatively recent in thyroid carcinomas
[34, 39–43]. The major part of these studies has been
focused on PD-L1 protein, while only one was conducted on
PD-L1 mRNA [34, 39–43]. Moreover, few studies examined
the CTLA-4 ligand (CD80 and CD86) gene expression at the
protein level in thyroid cancer cell lines and tissues,
including PTC and ATC tissues [44–47].
Considering the importance of the identiﬁcation of new
prognostic molecular markers for aggressive DTC, the neces-
sity of new therapeutic approaches for the most aggressive
thyroid cancers [26–31], and the promising results obtained
by inhibitors of immune checkpoint molecules in clinical tri-
als [48], the aim of this work was to investigate the expres-
sion, at the mRNA level, of CTLA-4 and PD-1 ligands in a
case study consisting of 94 PTC and 11 ATC tissues.
Variations in the mRNA levels were then correlated with
clinicopathological features to evaluate their possible
prognostic relevance.
The results suggested a prognostic value for CD80 gene
expression in PTC patients and, of note, a role of decreased
CD80 expression in ATC progression.
2. Materials and Methods
2.1. Tissue Samples, Histology, and Patient’s Staging. Normal
thyroid tissues and matched PTC tissues were obtained from
surgical specimens of 94 patients (19 males and 75 females,
age range 11–83 yr, median 44 yr) who underwent total
thyroidectomy at the Department of Surgical Sciences,
“Sapienza” University of Rome (37 patients) or at the
Department of Medicine, University of Padua (57 patients)
(Supplementary data ﬁle (available here)). ATC tissues were
collected from surgical specimens of 11 patients (4 males
and 7 females, age range 57–79 yr, median 69 yr) who had
surgery at the Department of Medicine, University of
Padua (6 patients) or at the Department of Clinical and
Experimental Medicine of Pisa (5 patients) (Supplementary
data ﬁle). All the patients gave their informed consent, and
the study was approved by the local ethical committee
(Protocol number 2615). Tissue samples were collected,
quickly frozen in liquid nitrogen, and stored at −80°C until
use. Of the 94 PTC patients, 72 exhibited the classical
variant, 17 the follicular variant, 3 the tall cells variant, and
2 the oncocytic variant. The histological diagnoses were
made independently by two diﬀerent histopathologists
according to the World Health Organization classiﬁcation
[49]. At the time of surgery, lymph node metastases were
found in 39 patients. Following TNM staging, 59 patients
were at stage I, 1 at stage II, 28 at stage III, and 6 at stage
IV. Approximately 40 to 50 days after intervention, all the
patients underwent radioiodine treatment followed by
thyroid hormone replacement therapy. To ascertain their
disease-free condition, 4 to 5 months after intervention, all
the patients were controlled by neck ultrasound and serum
Tg measurement. Recurrences were diagnosed by
determining serum Tg levels either in basal conditions or
upon recombinant human TSH stimulation, FNA cytology
and/or Tg determination in the FNA washout from lymph
nodes, 131I whole body scan, and histological analysis of
surgically resected lesions. The follow-up included 79 PTC
patients (mean 57.1± 36.7 months, range 5–141 months),
52 of which were at TNM stage I. During the follow-up, 16
recurrences were recorded (Supplementary data ﬁle).
Regarding ATC patients, they all died from the disease
(survival time range 1–25 months, median 6 months).
2.2. Determination of BRAFV600E Mutation. Genomic DNA
was extracted from the frozen tissues using the DNeasy Blood
and Tissues kit (QIAGEN, Milan, Italy) according to the
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manufacturer’s protocol. The BRAF status of exon 15 was
assessed by both direct sequencing and mutant allele-
speciﬁc PCR ampliﬁcation for the T to A substitution at
nucleotide 1799 (V600E), using the procedure previously
described [50].
2.3. Extraction and Analysis of mRNA. Frozen normal and
tumor thyroid tissues were homogenized with the ultraturrax
in Isol-RNA Lysis Reagent (FivePrime, San Francisco, CA,
USA), and total RNA was extracted. The ﬁrst cDNA strand
was synthesized from 5μg of RNA with M-MLV reverse
transcriptase and anchored oligo[dT]23 primers (Sigma-
Aldrich, Milan, Italy). Parallel controls for DNA contamina-
tion were carried out omitting the reverse transcriptase. The
templates obtained were used for quantitative PCR ampliﬁ-
cations of PD-L1, PD-L2, CD80, CD86, and three diﬀerent
housekeeping genes (GAPDH, RPL13A, and SDHA), previ-
ously validated [30], employing the LightCycler instrument
(Roche Diagnostics, Mannheim, Germany), the SYBR Pre-
mix Ex Taq II (Tli RNaseH Plus, Takara, Otsu, Shiga, Japan),
and speciﬁc primers listed in Table 1. Amplicon speciﬁcities
were checked by automated DNA sequencing (Bio-Fab
Research, Rome, Italy), evaluation of melting temperatures,
and electrophoresis on 2% agarose gel containing ethidium
bromide. Standard curves for all genes were created with ﬁve-
fold dilutions of a cDNAmix from human thyroid tissue. For
the relative quantiﬁcation of target genes, a normalization
factor computed as the geometric media of the 3 reference
genes was used, as previously described [28]. The fold
changes in gene expression were calculated between each
PTC tissue and its normal counterpart, while the ATC sam-
ples, for which the normal matched tissues were not avail-
able, were compared to a pool of 10 normal thyroid tissues.
Data analysis was performed with the Relative Expression
Software Tool (REST 2009) using as normalization factor
the geometric mean of the abovementioned housekeeping
genes, whose expression was proven to be stable among nor-
mal, PTC, and ATC tissues in preliminary experiments (data
not shown).
2.4. Statistical Analysis. The Shapiro-Wilk test was used to
evaluate the distribution of data relative to the mRNA level
of the diﬀerent analyzed genes. Then, the nonparametric
Mann–Whitney U test was used to calculate the statistical
signiﬁcance of diﬀerences in the expression levels of the tar-
get genes in female versus male patients, in the classical
PTC variant versus other variants, in BRAFV600E mutated
versus BRAF wild-type (BRAFWT) PTC, in metastatic (N1)
versus nonmetastatic (N0) PTC, in T1-2 versus T3-4 tumor
sizes, in TNMI-II versus TNMIII-IV stages, in the presence or
absence of recurrence, and in normal thyroid tissues versus
ATC. The nonparametric Fisher’s exact test was used to eval-
uate diﬀerences amongst the following groups of patients
referring to clinicopathological parameters: (i) BRAFWT ver-
sus BRAFV600E, (ii) BRAFWT with increased mRNA levels of
both PD-L1 and PD-L2 versus BRAFV600E with increased
mRNA levels of both PD-L1 and PD-L2, (iii) BRAFWT with
increased mRNA levels of PD-L1 and/or PD-L2 versus
BRAFV600E with increased mRNA levels of PD-L1 and/or
PD-L2. The correlation of mRNAs with each other and with
patient’s age was evaluated by Spearman’s rho test. The cor-
relation strength was interpreted considering the correlation
coeﬃcient value (r): 0< r< 0.19, very weak; 0.20< r< 0.39,
weak; 0.40< r< 0.59, moderate; 0.60< r< 0.79, strong;
0.80< r< 1.00, very strong [51]. The impact of gene expres-
sion on disease-free interval was assessed by the Kaplan-
Meier analysis combined with Mantel-Cox log-rank. For
the latter, values were classiﬁed based on the following cri-
teria: fold change> 1.5 as “increased”; fold change< 0.5 as
“decreased”; and 0.5≤ fold change≤ 1.5 as “unvaried.” All
statistical analyses were carried out with the SPSS software
(IBM, Armonk, NY, USA), and the results were considered
signiﬁcantly diﬀerent if the pertaining p values were lower
than 0.05.
3. Results
3.1. Expression of CTLA-4 and PD-1 Ligands in Papillary
(PTC) and Anaplastic (ATC) Thyroid Cancer Tissues. The
analysis of the mRNA levels of CTLA-4 and PD-1 ligands
in PTC samples, compared to normal matched tissues,
revealed that the expression of all transcripts was dysregu-
lated in the majority of cases (Figure 1). Considering a
threshold fold change of 0.5 for reductions and of 1.5 for
Table 1: Sequence, exon position, and amplicon size of the primers used in quantiﬁcation of human PD-1 and CTLA-4 gene expression in
thyroid carcinomas.
Gene Primer sequence Exon Amplicon size (bp)
PD-L1
5′-TATGCCTTGGTGTAGCACTGAC-3′ 5
139
5′-CCAATGCTGGATTACGTCTC-3′ 7
PD-L2
5′-TTTCATAGCCACAGTGATAGCC-3′ 5
134
5′-TCCCAAGACCACAGGTTCAG-3′ 7
CD80
5′-CCTGGCTGAAGTGACGTTATC-3′ 3
143
5′-TTTCCAACCAGGAGAGGTGAG-3′ 4
CD86
5′-CAACACAATGGAGAGGGAAGAG-3′ 6
89
5′-AAACACGCTGGGCTTCATC-3′ 7
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increments, the mRNA levels of PD-L1 were decreased in 14
(14.9%) and increased in 40 (42.6%) out of 94 PTC tissues
analyzed, PD-L2 mRNA was reduced in 24 (25.5%) cases
and increased in 33 (35.1%) cases, CD80 mRNA level was
reduced in 32 (34.0%) and increased in 22 (23.4%) cases,
and CD86 mRNA level was reduced in 13 (13.8%) and
increased in 46 (48.9%) cases. The transcript levels were
investigated also in 11 ATC tissues, although CD86 mRNA
was analyzed only in 8 ATC samples due to the low amount
of the available tissues. Even in ATC, the results showed that
the expression of all genes analyzed was deregulated
(Figure 2). In particular, the PD-L1 mRNA was decreased
in 3 (27.27%) and increased in 3 (27.27%) out of 11 ATC tis-
sues analyzed, PD-L2mRNAwas reduced in 4 (36.36%) cases
and increased in 2 (18.18%) cases, CD80mRNA was reduced
in 9 (81.82%) and increased in 1 (9.09%) cases, and CD86
mRNA was reduced in 2 (25.00%) and increased in 3
(37.50%) cases out of 8 ATC analyzed.
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Figure 1: Relative expression levels of PD-L1, PD-L2, CD80, and CD86mRNAs in PTC tissues. The fold changes were calculated considering
the mRNA values of normal matched thyroid tissues equal to one. Referring to mRNA fold change, three groups are showed (i.e., reduced,
unchanged, and increased). For each group, “n” indicates the number of cases. The small bars in the graph indicate the median values.
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Signiﬁcant moderate to strong positive correlations were
recorded between PD-L1 and PD-L2, PD-L1 and CD80, and
PD-L2 and CD86 in thyroid cancer tissues (Table 2).
3.2. CTLA-4 and PD-1 Ligand Expression in PTC Tissues with
and without BRAFV600E Mutation. To assess the eﬀect of
BRAFV600E mutation on CTLA-4 and PD-1 ligand expres-
sion, we analyzed the mRNA levels of each ligand in 76
PTC tissues for which the BRAF gene status was available.
Of these, 38 (50.0%) PTC harbored the BRAFV600E mutation
while 38 had the BRAFWT. The results of univariate analysis,
reported in Table 3, showed that the BRAFV600E mutation
associated with increased PD-L1 and PD-L2 transcripts in
PTC tissues, while no association could be found between
BRAF status and CTLA-4 ligands.
In order to assess if the relationship between BRAFV600E
mutation and PD-1 ligands had implications on clinicopath-
ological parameters, we performed an analysis comparing the
following groups: (i) patients with BRAFWT and increased
mRNA levels of both PD-L1 and PD-L2 versus patients with
BRAFV600E mutation and increased mRNA levels of both
PD-L1 and PD-L2 and (ii) patients with BRAFWT and
increased mRNA levels of at least one PD1 ligand versus
patients with BRAFV600E mutation and increased mRNA
levels of at least one PD1 ligand. Firstly, we compared
BRAFWT versus BRAFV600E patients referring to clinicopath-
ological parameters (Table 4). Signiﬁcant diﬀerences in PTC
histology and the TNM stage emerged (Table 4). Nonethe-
less, by grouping patients based on both BRAF mutational
status and augmentation of PD-1 ligand mRNAs, any signif-
icant diﬀerence was encountered (data not shown).
3.3. Association with Clinicopathological Parameters and
Prognostic Relevance of CTLA-4 and PD-1 Ligand
Expression in PTC Patients. Since an independent association
was previously reported between PD-L1 expression and
tissue lymphocytic inﬁltration [39], we decided to evaluate
the fold change of the mRNA level of PD-1 and CTLA-4
ligands in PTC patients with or without thyroiditis. No
diﬀerences were noticed between the two groups. Likewise,
univariate analysis showed no statistically signiﬁcant
association between the mRNA expression of CTLA-4 and
PD-1 ligands and gender, age, TNM stage, and recurrences
(Table 3). However, a signiﬁcant association emerged
between mRNA levels of PD-L1, PD-L2, and CD80 and
histology. Speciﬁcally, higher PD-L1 mRNA levels were
associated with the classical PTC variant, and lower mRNA
levels of PD-L2 and CD80 were associated with the
follicular PTC variant (Table 3). The statistical analysis also
evidenced an association between higher CD86 mRNA
levels and tumor size. Lastly, lymph node metastases were
found to associate with increased PD-L2, while the reduced
CD80 mRNA levels were related to the absence of lymph
node metastases. Kaplan-Meier analysis, performed by
dividing the PTC patients in three groups with decreased,
unchanged, or increased gene expression, showed that PD-1
ligands did not signiﬁcantly aﬀect the disease-free survival
(DFS). Interestingly, patients with increased CD80 gene
expression had a better DFS (p = 0 011) compared to those
with either unchanged or decreased CD80 expression
(Figure 3). A similar trend (p = 0 053) was observed for
CD86 expression.
4. Discussion
The ﬁeld of cancer immunotherapy promises great results in
reducing tumor growth and in achieving complete remission,
especially in combination with other therapies. In the past
decades, several studies focused on the immune checkpoints
mediated by PD-1 and CTLA-4 and their pharmacological
inhibition, in order to restrain neoplastic growth [14–19].
The inhibition of one or both the immune checkpoints
immediately appeared as a promising therapeutic strategy
and, at present, many clinical trials are ongoing for diﬀerent
cancer types, while others were concluded with drug
approval by the FDA [23, 24].
The investigation of PD-1 and CTLA-4 ligand expression
and their prognostic value is relatively recent in thyroid
carcinomas, and only one study examined PD-L1
expression at the mRNA level [34, 39–43].
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Figure 2: Relative expression levels of the PD-L1, PD-L2, CD80, and
CD86 mRNAs in ATC tissues. The fold changes were calculated
considering the mRNA values of a pool of 10 normal thyroid
tissues equal to one. The small bars in the graph indicate the
median values.
Table 2: Correlation among the expression levels of PD-1 and
CTLA-4 ligands.
Correlation coeﬃcient and p values
PD-L1 PD-L2 CD80 CD86
PD-L1
1.000 0.693 0.539 0.405
— <0.001 <0.001 <0.001
PD-L2
1.000 0.644 0.598
— <0.001 <0.001
CD80
1.000 0.509
— <0.001
CD86
1.000
—
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Here, we showed that mRNA levels of PD-1 and CTLA-4
ligands in PTC samples were signiﬁcantly deregulated in the
majority of cases, compared to normal matched tissues. Con-
cerning PD-L1 expression, our data are in agreement with
those of previous studies showing an augmented expression
in a subset of PTC tissues [34, 39–43]. To our knowledge,
no one investigated the expression of PD-L2 in thyroid carci-
nomas. In the present study, we found a strong correlation
between PD-L2 and PD-L1 gene expression, with PD-L2
upregulated and downregulated, respectively, in 35.1% and
23.4% of PTC cases. Concerning CD80 and CD86, only two
previous studies analyzed their expression in PTC by immu-
nohistochemistry, with conﬂicting results [46, 47]. In our
ﬁndings, the correlation analysis evidenced a moderate sig-
niﬁcant covariation between CD80 and CD86 mRNA levels
in thyroid cancer tissues. In particular, the expression of
CD80 and CD86 was augmented, respectively, in 23.4% and
48.9% of PTC and diminished in 34% and 13.8% of PTC.
The expression of PD-1 and CTLA-4 ligands was also
found deregulated in ATC tissues. Interestingly, CD80
mRNA was reduced in almost all ATC tissues analyzed. In
addition, a lower CD80 mRNA level was observed to
associate with the more aggressive follicular PTC variant.
These ﬁndings corroborate previous evidence showing
reduced expression of CD80 in many cancer types (i.e., mel-
anoma, myeloma, acute myeloid leukemia, bladder, and
colon carcinoma) and are in agreement with the observation
of its lower expression in poorer diﬀerentiated esophageal
cancers, compared to well- and moderate-diﬀerentiated ones
[21, 52, 53]. Thus, it may be tempting to speculate that
reduced CD80 gene expression may confer an advantage to
tumor growth. In particular, the lack of CD80 expression
has been suggested to be suﬃcient to evade immune surveil-
lance [51]. In fact, the dysregulated expression of both CD80
and CD86 could negatively aﬀect CTL and Treg functions
allowing tumor spread [54, 55]. In addition, transgenic
expression of CD80 has been shown to induce tumor
regression in xenograft experiments and human clinical
trials [56–58]. Considering the diﬀerent aﬃnity of CD86
and CD80 for CD28 and CTLA-4, respectively, and the
constitutive expression of CTLA-4 in Treg cells, cancer cells
could induce antigen tolerance towards themselves by
modulating Treg cell functions [57]. Such hypotheses
appear to be in agreement with our results from Kaplan-
Table 3: Univariate statistical analysis of PD1 and CTLA4 ligand gene expression and PTC patient characteristics and clinicopathological
features. For each clinicopathological feature, the number of patients in each group was reported in brackets. For each gene, the median
value of mRNA fold change between PTC tissue and its normal counterpart is reported.
PD-L1 p value PD-L2 p value CD80 p value CD86 p value
Gender
Male (n = 19) 1.68
0.468
1.48
0.346
0.97
0.210
1.98
0.940
Female (n = 75) 1.26 0.99 0.71 1.42
Age (y/o)
Corr. coeﬀ. 0.131 0.209 0.161 0.122 0.141 0.176 −0.003 0.979
Hystology
Classical variant (n = 72) 1.41
0.002
1.11
0.033
0.89
0.046
1.57
0.059
Follicular variant (n = 17) 1.02 0.52 0.51 1.27
BRAF
Wild type (n = 38) 1.21
0.026
0.86
0.035
0.72
0.355
1.21
0.081
V600E (n = 38) 1.79 1.41 0.86 1.65
pT
T1-2 (n = 39) 1.05 0.060 0.91 0.053 0.63 0.132 1.24 0.040
T3-4 (n = 55) 1.52 1.22 0.92 1.78
pN
N0 (n = 55) 1.10 0.062 0.80 0.002 0.55 0.010 1.47 0.615
N1 (n = 39) 1.37 1.54 1.02 1.48
TNM stage
I-II (n = 60) 1.12
0.118
0.97
0.113
0.67
0.077
1.43
0.292
III-IV (n = 34) 1.54 1.46 0.95 1.88
Recurrence
No (n = 63) 1.28
0.626
1.03
0.903
0.81
0.244
1.39
0.696
Yes (n = 16) 1.25 1.03 0.78 1.25
Thyroiditis
No (n = 57) 1.34
0.690
1.07
0.892
0.69
0.129
1.68
0.144
Yes (n = 37) 1.10 1.03 0.92 1.35
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Meier analysis, showing a signiﬁcative association between
CD80 mRNA upregulation with a higher DFS probability
in PTC patients. Moreover, although no signiﬁcative
diﬀerence was assessed, there was a trend toward a
longer DFS when CD86 was upregulated. In contrast
with the hypothesis of protective role of higher CD80/
CD86 gene expression, we also found that upregulated
expression of CD86 associated with a greater tumor size
(pT3-4) and that nonmetastatic PTC (pN0) had a reduced
expression of CD80 compared to metastatic ones (pN1).
Indeed, these observations were also in contrast with the
previously reported results on esophageal cancer, where
the lower CD80 protein level was associated with the
presence of lymph node metastasis [53]. Although these
diﬀerences may be due to tumor-speciﬁc biology, they
also highlight the necessity to corroborate our ﬁndings
on larger case studies.
Regarding lymph node metastasis, we also observed an
association with increased PD-L2 expression, and conceiv-
ably PD-L1, at the mRNA level. To our knowledge, no one
investigated the relationship between PD-L2 and thyroid
cancers. However, in breast cancer, a signiﬁcant association
between PD-L2 protein and the lymph node metastasis pres-
ence was observed [58].
Concerning the other clinicopathological parameters, in
accordance with Shi et al. [42], we observed the higher PD-
L1 mRNA level associated with the classical variant of PTC.
The signiﬁcative diﬀerence also interested PD-L2, and in our
best knowledge, this is the ﬁrst work that investigates the
association of PD-L2 expression with PTC histology. Diﬀer-
ently from Cuhna and colleagues, we did not ﬁnd other sig-
niﬁcative associations between PD-1 ligands mRNA and
clinicopathological features. In particular, they reported an
association between higher tumor stage and the increased
PD-L1 gene expression [39], while we cannot statistically
conﬁrm this result, for both PD-L1 and PD-L2, probably
because we tested only PTC and a smaller case study.
Diﬀerently from the PD-L1 protein, which other authors
demonstrated to be associated with a greater risk of recur-
rence and with a reduced DFS, our results suggested that
the PD-1 ligand mRNA expression cannot be considered as
prognostic markers for PTC [40, 42, 46]. The mRNA levels
of PD-L1 and PD-L2 were almost identical in patients with
and without recurrence and did not signiﬁcantly inﬂuence
the DFS probability. Further studies on larger cohorts and
the parallel analysis of mRNA and protein from the same
patients could clarify this aspect.
Lastly, PTC tissues with BRAFV600E expressed higher PD-
L1 levels than BRAFWT tumors. The results appear to be in
accordance with those of Angell et al. [34]. Moreover, we also
observed a higher PD-L2 mRNA level in BRAFV600E tumors
compared to BRAFWT ones. Our data corroborate the idea
that PD-L1 and PD-L2 gene expression is a downstream tar-
get of BRAF signaling, as previously suggested for PD-L1 in
Table 4: Results from Fisher’s exact test to evaluate the association of clinicopathological features and the following groups: BRAFWT (38
patients) and BRAFV600E (38 patients).
BRAFWT BRAFV600E p value
Gender
Male n = 9 n = 9
1.000
Female n = 29 n = 29
Age (y/o)
Medium value 41.36 52.17
Hystology ∗
Classical variant n = 27 n = 33
0.046
Follicular variant n = 9 n = 2
pT
T1-2 n = 19 n = 11
0.100
T3-4 n = 19 n = 27
pN
N0 n = 18 n = 23
0.357
N1 n = 20 n = 15
TNM stage
I-II n = 29 n = 18
0.017
III-IV n = 9 n = 20
Recurrence ∗∗
No n = 28 n = 28
0.569
Yes n = 9 n = 6
∗Other PTC variants were excluded because of their small number. ∗∗Information about recurrence was not available for 1 patient in group 1 and 3 patients in
group 2.
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thyroid carcinoma and demonstrated in myeloma [34, 59].
However, our results appear to suggest that the major tumor
aggressiveness conferred by BRAFV600E could be independent
from the immunosuppressive action of PD-L1 and PD-L2.
5. Conclusions
In conclusion, the present work conﬁrmed the overall dereg-
ulation of PD-1 and CTLA-4 ligands in PTC and ATC tissues
and suggested a possible prognostic value for CD80 gene
expression and a relevant role in ATC progression that could
be of interest for the design of novel therapeutic strategies.
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